Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia

FLT3 gene mutations, either internal tandem duplication (ITD) or D835 point mutations, have been studied extensively in acute myeloid leukemia and myelodysplastic syndrome (MDS). Little is known about FLT3 mutations in chronic myeloproliferative diseases (CMPDs) or their relationship with V617F JAK2...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical pathology Vol. 126; no. 4; pp. 530 - 533
Main Authors Lin, Pei, Jones, Dan, Medeiros, L Jeffrey, Chen, Weina, Vega-Vazquez, Francisco, Luthra, Rajyalakshmi
Format Journal Article
LanguageEnglish
Published England 01.10.2006
Subjects
Blast Crisis - genetics
Blast Crisis - metabolism
Blast Crisis - pathology
Bone Marrow - metabolism
Bone Marrow - pathology
Chronic Disease
DNA Mutational Analysis
DNA, Neoplasm - analysis
fms-Like Tyrosine Kinase 3 - genetics
fms-Like Tyrosine Kinase 3 - metabolism
Leukemia, Myeloid, Chronic-Phase - genetics
Leukemia, Myeloid, Chronic-Phase - metabolism
Leukemia, Myeloid, Chronic-Phase - pathology
Myeloproliferative Disorders - genetics
Myeloproliferative Disorders - metabolism
Myeloproliferative Disorders - pathology
Philadelphia Chromosome
Point Mutation
Polymerase Chain Reaction
Retrospective Studies
Online AccessGet full text

Cover

More Information
Summary:FLT3 gene mutations, either internal tandem duplication (ITD) or D835 point mutations, have been studied extensively in acute myeloid leukemia and myelodysplastic syndrome (MDS). Little is known about FLT3 mutations in chronic myeloproliferative diseases (CMPDs) or their relationship with V617F JAK2 mutations. We analyzed bone marrow samples from 142 patients with Philadelphia (Ph) chromosome- CMPD or CMPD/MDS and from 119 patients with Ph+ chronic myeloid leukemia (CML) using a multiplex polymerase chain reaction assay. FLT3 mutations, 11 ITD and 2 D835, were detected in 13 (9.2%) patients with CMPD or CMPD/MDS, 7 in blast phase and 6 in chronic phase. Analyses for JAK2 mutations in 11 of 13 cases were all negative. By contrast, no FLT3 mutations were detected in CML, including 108 chronic and 11 blast phase cases. FLT3 mutations occur in approximately 10% of CMPD and CMPD/MDS but are not observed in JAK2+ CMPD or in CML.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9173
DOI:10.1309/JT5BE2L1FGG8P8Y6